Aspiculamycin, a new cytosine nucleoside antibiotic. IV. Antimycoplasma activity of aspiculamycin in vitro and in vivo.
D000128:Acholeplasma laidlawii / Q000187:drug effects; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D003470:Culture Media; D003597:Cytosine Nucleotides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D007740:L Forms / Q000187:drug effects; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D009174:Mycoplasma / Q000187:drug effects*; D009175:Mycoplasma Infections / Q000188:drug therapy*; D009176:Mycoplasma mycoides / Q000187:drug effects; D011741:Pyrimidine Nucleosides; D013997:Time Factors
D000900:Anti-Bacterial Agents; D003470:Culture Media; D003597:Cytosine Nucleotides; D011741:Pyrimidine Nucleosides; C004942:gougerotin